NexImmune, Inc.
NEXI · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,025 | $1,495 | $870 | $619 |
| Gross Profit | -$1,025 | -$1,495 | -$870 | -$619 |
| % Margin | – | – | – | – |
| R&D Expenses | $18,257 | $47,148 | $37,456 | $17,839 |
| G&A Expenses | $13,000,624 | $15,934 | $15,799 | $10,012 |
| SG&A Expenses | $9,910 | $15,934 | $15,799 | $10,012 |
| Sales & Mktg Exp. | -$12,990,714 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1,495 | -$870 | -$619 |
| Operating Expenses | $28,168 | $61,588 | $52,385 | $27,232 |
| Operating Income | -$29,192 | -$63,083 | -$53,256 | -$27,851 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3,152 | $577 | $2,354 | -$2,015 |
| Pre-Tax Income | -$32,344 | -$62,506 | -$50,902 | -$29,866 |
| Tax Expense | $0 | -$576,690 | $844 | $1,773 |
| Net Income | -$32,344 | $514,184 | -$51,745 | -$31,639 |
| % Margin | – | – | – | – |
| EPS | -30.82 | 534.29 | -56.67 | -34.76 |
| % Growth | -105.8% | 1,042.8% | -63% | – |
| EPS Diluted | -30.82 | 534.29 | -56.67 | -34.76 |
| Weighted Avg Shares Out | 1,049 | 962 | 913 | 910 |
| Weighted Avg Shares Out Dil | 1,049 | 962 | 913 | 910 |
| Supplemental Information | – | – | – | – |
| Interest Income | $698 | $664 | $53 | $21 |
| Interest Expense | $0 | $0 | $905 | $1,683 |
| Depreciation & Amortization | $1,025 | $1,495 | $870 | $619 |
| EBITDA | -$28,168 | -$61,011 | -$49,126 | -$27,564 |
| % Margin | – | – | – | – |